- The Consumables segment of Vitrolife AB (VTRLY, Financial) reported a strong 9% growth in Q2 2025, excluding discontinued operations.
- Americas region sales increased by 5%, while EMEA saw a decline of 3% and APAC remained flat.
- Overall, Vitrolife's earnings were affected by a negative currency impact, causing a 7% decrease in SEK sales.
Vitrolife AB (VTRLY), a leader in the medical devices sector, reported its Q2 2025 financial results, showcasing a mixed performance. The company's total sales amounted to SEK 871 million, reflecting no growth in local currencies and a 7% decrease in Swedish krona (SEK) due to an adverse currency effect of 8%. Despite these challenges, Vitrolife achieved a 3% organic growth in local currencies, excluding discontinued business operations.
In terms of regional performance, the Americas region showed resilience with a 5% increase in sales. However, the EMEA region experienced a 3% decline, though it managed a 5% growth excluding discontinued business. The APAC region saw no significant change, remaining flat.
The performance across product segments varied. The Consumables segment experienced robust growth, posting a 9% increase excluding discontinued operations. Conversely, Technologies declined by 6%, and the Genetics segment managed a modest 3% growth.
Vitrolife reported a decline in its EBITDA margin to 27.8% from the previous 34.7%, influenced by currency challenges. The company's net income stood at SEK 100 million, translating to earnings per share of SEK 0.74. Furthermore, the operating cash flow remained positive at SEK 151 million.
Strategically, Vitrolife made significant advancements with the acquisition of a leading stake in AutoIVF, expanding its footprint in the fertility technology market.
